Moroctocog alfa

Moroctocog alfa
Clinical data
Trade names ReFacto
AHFS/Drugs.com UK Drug Information
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
ChemSpider
  • none
Chemical and physical data
Molar mass 170 kg/mol

Moroctocog alfa (trade name ReFacto) is a recombinant antihemophilic factor genetically engineered from Chinese hamster ovary (CHO) cell line. Chemically it is a glycoprotein.[1] It is manufactured by Genetics Institute, Inc. and used to control and prevent hemorrhagic bleeding and prophylaxis associated with surgery or to reduce the number of spontaneous bleeding episodes in patients with hemophilia A. It is partially a recombinant coagulation factor VIII since it has an amino acid sequence which compares to the 90 + 80 kDa form of factor VIII (BDDrFVIII).[2] It also has posttranslational modifications which are similar to those of the plasma-derived molecule. It can not prevent hemorrhagic bleeding associated with von Willebrand's disease since it is not a von Willebrand factor.

References

  1. ↑ http://www.abopharmaceuticals.com/ProductSheets/Refacto.pdf
  2. ↑ (PDF) https://web.archive.org/web/20100531074853/http://www.ema.europa.eu/humandocs/PDFs/EPAR/Refacto/058999en6.pdf. Archived from the original (PDF) on May 31, 2010. Retrieved March 8, 2010. Missing or empty |title= (help)


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.